Inhibrxの推定成長EPS Q/Q
Inhibrxの推定成長EPS Q/Qは何ですか。
Inhibrx, Inc.の推定成長EPS Q/Qは43.64%です。
推定成長EPS Q/Qの定義は何ですか。
期待される四半期ごとのEPS成長率は、過去四半期の業績と比較して、次の四半期の企業EPSの推定増加です。
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
NASDAQのセクタHealth Careにおける推定成長EPS Q/Qの企業と比べるInhibrx
Inhibrxは何をしますか。
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrxと類似の推定成長eps q/q
- SNC-Lavalinの推定成長EPS Q/Qは43.48%です。
- Ideal Power Incの推定成長EPS Q/Qは43.48%です。
- Heritage Commerceの推定成長EPS Q/Qは43.48%です。
- Herc Incの推定成長EPS Q/Qは43.50%です。
- RCI Industries & Technologiesの推定成長EPS Q/Qは43.61%です。
- ArcBest Corpの推定成長EPS Q/Qは43.63%です。
- Inhibrxの推定成長EPS Q/Qは43.64%です。
- Viking Therapeutics Incの推定成長EPS Q/Qは43.75%です。
- BioCardiaの推定成長EPS Q/Qは43.75%です。
- BioCardiaの推定成長EPS Q/Qは43.75%です。
- Keyeraの推定成長EPS Q/Qは43.75%です。
- ChemoCentryx Incの推定成長EPS Q/Qは43.75%です。
- Great Southernの推定成長EPS Q/Qは43.86%です。